Return-Path: jm@dogma.slashnull.org
Delivery-Date: Fri, 19 Jan 2001 13:06:12 +0000
Return-Path: <jm@dogma.slashnull.org>
Delivered-To: jm@netnoteinc.com
Received: from dogma.slashnull.org (dogma.slashnull.org [212.17.35.15])
	by mail.netnoteinc.com (Postfix) with ESMTP id F3AC3114092
	for <jm@netnoteinc.com>; Fri, 19 Jan 2001 13:06:08 +0000 (Eire)
Received: (from jm@localhost)
	by dogma.slashnull.org (8.9.3/8.9.3) id NAA03243
	for jm@netnoteinc.com; Fri, 19 Jan 2001 13:06:08 GMT
Received: from XeNT.ics.uci.edu (xent.ics.uci.edu [128.195.21.213])
	by dogma.slashnull.org (8.9.3/8.9.3) with ESMTP id NAA03238
	for <jm@jmason.org>; Fri, 19 Jan 2001 13:06:04 GMT
From: emed11@libero.it
Received: from blue.mydomain.com (blue.mydomain.com [208.184.130.52])
	by XeNT.ics.uci.edu (8.8.5/8.8.5) with ESMTP id FAA13612
	for <fork@xent.ics.uci.edu>; Fri, 19 Jan 2001 05:05:24 -0800 (PST)
Received: from ns.paknet.com.pk (unknown [203.135.0.29])
	by blue.mydomain.com (Postfix) with ESMTP id 166D334082
	for <fork@xent.com>; Fri, 19 Jan 2001 02:30:19 -0500 (EST)
X-Antispam: rblchk: (RSS) 3 Relayed through blacklisted site 203.135.0.29
Received: from libero.it (localhost [127.0.0.1])
	by ns.paknet.com.pk (8.11.0/8.11.0) with SMTP id f0J3fTa00334
	for <fork@xent.com>; Thu, 18 Jan 2001 22:41:40 -0500 (GMT)
To: fork@xent.com
Subject: Obtain Biotech IPOs!    59
Date: Thu, 18 Jan 2001 12:38:16
Message-Id: <372.821353.426507@libero.it>
Reply-To: emed11@libero.it
Mime-Version: 1.0
Content-Type: text/html; charset="us-ascii"
Sender: jm@dogma.slashnull.org

<html>

<head>
<meta http-equiv="Content-Type" content="text/html; charset=windows-1252">
<meta name="GENERATOR" content="Microsoft FrontPage 4.0">
<meta name="ProgId" content="FrontPage.Editor.Document">
<title></title>
</head>

<body bgcolor="#CCCCCC">

<div align="center">

<table border="2" width="550" cellpadding="14" cellspacing="5" bordercolor="#003366" bordercolorlight="#003366" bordercolordark="#003366">
<tr>
<td width="100%" bgcolor="#FFFFFF">

<p class="MsoBodyText" align="center"><b><font color="#003399" size="4" face="Verdana">Help Beta Test Our Site and Be Eligible to Purchase Shares of Future IPOs
In Which We Participate**</font></b></p>

<p class="MsoBodyText" align="left" style="text-align:left"><font size="2" face="Arial">eMedsecurities
has selected you as a possible participant to help test our online stock-trading
engine for knowledge-based investing in the life sciences. For your cooperation,
<b> you will be eligible to purchase shares of future IPOs</b> in which
we participate, for as long as
you maintain your account with us. This is limited to only <b>50 qualified
testers!&nbsp;</b>  <a href="mailto:emedsec@libero.it">Request More Information</a>.**</font></p>

<p class="MsoBodyText" align="center"><b><font size="3" face="Verdana" color="#003399">eMedsecurities… The Cure for the Common Portfolio!</font></b></p>

<p class="MsoBodyText" align="left" style="text-align:left"><font size="2" face="Arial">eMedsecurities provides you with a wealth of information, all compiled
in a single, easy-to-use resource.&nbsp; Learn about new research and upcoming treatments
for muscular dystrophy, multiple sclerosis, Parkinson's disease, Huntington's
chorea and much more.&nbsp; Obtain critical investment
information about the companies that are developing these treatments.&nbsp; eMedsecurities empowers you to make more informed investment decisions.
<a href="mailto:emedsec@libero.it">Request More Information</a>.**</font></p>

<p class="MsoNormal"><b><font size="2" face="Arial">Participation in eMedsecurities’ Beta Test allows you:</font></b></p>

<ul>
<li>

<p class="MsoNormal" style="mso-list: l1 level1 lfo2; tab-stops: list .5in"><b><font size="2" face="Arial" color="#003399">Eligibility to purchase shares
of IPOs in which eMedsecurities participates for as long as you maintain your account**</font></b></li>
<li>

<p class="MsoNormal" style="mso-list: l1 level1 lfo2; tab-stops: list .5in"><b><font size="2" face="Arial" color="#003399">Valuable research of the entire
product pipeline of companies, including stages of clinical development, by industry or specific disease</font></b></li>
<li>

<p class="MsoNormal" style="mso-list: l1 level1 lfo2; tab-stops: list .5in"><b><font size="2" face="Arial" color="#003399">Useful information about industry trends, recent developments and upcoming IPOs</font></b>
</li>
<li>

<p class="MsoNormal" style="mso-list: l1 level1 lfo2; tab-stops: list .5in"><b><font size="2" face="Arial" color="#003399">Commitment to customer service featuring our Live Customer Service Online</font></b></li>
<li>

<p class="MsoNormal" style="mso-list: l1 level1 lfo2; tab-stops: list .5in"><b><font size="2" face="Arial" color="#003399">Dedication to fast trade executions at the best possible
price.</font></b></li>
</ul>

<p align="left"><font size="2" face="Arial">The following guidelines will explain what we expect from an eMedsecurities Beta Tester:</font></p>

<ul>
<li>

<p align="left"><font size="2" face="Arial">Open a funded eMedsecurities account</font></li>
<li>

<p align="left"><font size="2" face="Arial">Visit our online trading site once a
week</font></li>
<li>

<p align="left"><font size="2" face="Arial">Execute trades through our web site in accordance with your normal
practice</font></li>
<li>

<p align="left"><font size="2" face="Arial">Submit feedback to eMedsecurities' development team through a
questionnaire sent via email</font></li>
<li>

<p align="left"><font size="2" face="Arial">Provide us with additional feedback regarding the site as needed.</font></li>
</ul>

<p align="left"><font size="2" face="Arial">The test is limited to only 50 Beta Testers so sign up now to be
considered!&nbsp; <a href="mailto:emedsec@libero.it">Request More Information</a>.**</font>

<p align="left"><b><font size="2" face="Arial">Please note:</font></b><font size="2" face="Arial">&nbsp;
All applications for the Beta Test must be
submitted by January 24, 2001 to be considered.</font>

<p align="left"><font face="Arial" size="2"><span style="mso-bidi-font-size: 12.0pt; mso-fareast-font-family: Times New Roman; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA">Please
be advised that your information will stay in our proprietary database and will
not be sold, traded, given or otherwise provided to outside vendors.&nbsp; We respect
your privacy.</span></font>

<p align="left">&nbsp;

<p align="left" style="line-height: 100%"><font face="Arial" size="1"><span style="mso-fareast-font-family: Times New Roman; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA">By
submitting your information, you implicitly state that this is something that
interests you and that you<br>
agree to receive periodic emails from
eMedsecurities.</span></font>

<p class="MsoNormal"><font size="1" face="Arial">Research indicated that you might benefit from
our offer.&nbsp; To be removed instantly and permanently from our database, simply
<a href="mailto:emed11@libero.it">click here</a>.&nbsp;
We respect all removal requests.</font></p>

<font size="1" face="Arial">**<b> Restrictions Apply:</b>&nbsp; <span style="color:red"><b>Beta
test not open to residents of:&nbsp; HI, IL, MI, MN, MS, NE, NH, TN, TX.</b></span>&nbsp;&nbsp;
Initial Public Offerings are considered speculative investments and as such may not be appropriate for every
investor. If an investor chooses to participate in IPOs, there are certain restrictions that apply:&nbsp; <b><span style="color:red">Flipping</span>- </b>The first time an investor sells his/her shares within the first 30 days the issue is trading in the secondary market, that investor will not be allocated
shares for the next 90 days following the sale.&nbsp; The second time that investor “flips”, they will not be allocated IPO shares for 180 days.&nbsp; The third time that investor “flips”, they lose their IPO allocations permanently.&nbsp;<span style="color:red">
<b>Transferring shares</b></span><b>- </b>If
the investor transfers IPO shares out of their account within the first 30 days the issue is trading in the secondary market, they will permanently lose their IPO allocations.&nbsp;
<b>Beta investors will be chosen from all the applicants based on their income, net worth and investing experience.&nbsp;</b>
IPO shares will only be allocated from transactions in which eMedsecurities
participates in the underwriting.
A0008-1-A2</font>
</td>
</tr>
</table>

</div>

</body>

</html>


